7th Jan 2026 15:20
IP Group PLC - London-based intellectual property commercialisation firm - Notes that portfolio company Pulmocide announced the termination of the Opera-T phase 3 study for opelconazole in refractory invasive pulmonary aspergillosis, a severe fungal infection of the lungs. Opelconazole is an experimental antifungal drug. IP has a 12.0% holding in Pulmocide valued at GBP28.1 million. Pulmocide, a biopharmaceutical firm, will conduct a thorough review of the unblinded data from the trial to determine potential next steps for the programme. IP adds that it expects to "significantly" reduce the carrying value of the asset and conduct further work as part of the year end process to fully gauge the appropriate level of its adjustment. IP says it "benefits from a strong pipeline of new and maturing companies, as well as a number of valuable licences, and remains confident of delivering meaningful returns for shareholders over the medium term."
Current stock price: 56.20 pence each, down 5.2% on Wednesday afternoon in London
12-month change: up 7.3%
By Tom Budszus, Alliance News slot editor
Comments and questions to [email protected]
Copyright 2026 Alliance News Ltd. All Rights Reserved.
Related Shares:
Ip Group